Company intelligence / Profile preview
LOK Enterprises
Uppsala, Swedenlokonpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lokon Pharma is a Swedish biotech company developing tumor microenvironment-targeted gene therapies using engineered oncolytic adenoviruses. Their lead program, LOAd703, has received orphan drug designation from both EMA and FDA for pancreatic cancer. Clinical data have been presented at major conferences such as ASCO and AACR, including studies of LOAd703 alone or in combination with chemotherapy or atezolizumab in melanoma and pancreatic cancer. The company collaborates with Roche on several clinical programs.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virus therapyGene therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on LOK Enterprises.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LOK Enterprises.